Abstract：【Objective】To evaluate the antiproliferation and pro-apoptotic effects of decitabine (DAC) combined with idarubicin (IDA) on OCI-AML3 cells harboring mutant DNMT3A.【Methods】OCI-AML3 cells were treated with different concentrations of IDA singly or combined with 2μM DAC for 48 h. Then, MTT and Annexin-V/PI were used to examine the proliferation and apoptosis of OCI-AML3 cells.【Results】IDA at relatively low concentrations (≤40nM) did not inhibit proliferation of OCI-AML3 cells significantly, but promoted proliferation inhibition remarkably when combined with 2μM DAC (P<0.01). DAC combined with IDA induced higher apoptotic rate compared to DAC or IDA as a single agent (P<0.001).【Conclusion】AML cells harboring mutant DNMT3A are primarily resistant to IDA at relatively low concentrations, while DAC can increase the susceptibility to IDA.
罗自勉,谭振清,娄典,尹亚飞,朱凯波. 地西他滨联合去甲氧柔红霉素对DNMT3A突变阳性AML细胞的增殖和凋亡的影响[J]. 医学临床研究, 2017, 34(6): 1058-1060.
LUO Zi-mian, TAN Zhen-qing, LOU Dian,et al. Anti-Proliferation and Pro-apoptosis Effects of Decitabine Combined with Idarubicin on AML Cells Harboring Mutant DNMT3A. JOURNAL OF CLINICAL RESEARCH, 2017, 34(6): 1058-1060.
[1] Marcucci G, Metzeler KH, Schwind S, et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia[J]. J Clin Oncol,2012,30(7):742-750. [2] Markova J, Michkova P, Burckova K, et al. Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia[J]. Eur J Haematol, 2012,88(2):128-135. [3] Renneville A, Boissel N, Nibourel O, et al. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association[J].Leukemia,2012;26(6):1247-1254. [4] Ribeiro AF, Pratcorona M, Erpelinck-Verschueren C, et al. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia[J].Blood,2012,119(24):5824-5831. [5] Tsai CH, Hou HA, Tang JL, et al. Genetic alterations and their clinical implications in older patients with acute myeloid leukemia[J].Leukemia,2016,30(7):1485-1492. [6] Guryanova OA, Shank K, Spitzer B, et al. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling[J].Nat Med,2016,22(12):1488-1495. [7] Metzeler KH, Walker A, Geyer S, et al. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia[J].Leukemia,2012,26(5):1106-1107. [8] Tiacci E, Spanhol-Rosseto A, Martelli MP, et al. The NPM1 wild-type OCI-AML2 and the NPM1-mutated OCI-AML3 cell lines carry DNMT3A mutations[J].Leukemia,2012,26(3):554-557. [9] Russler-Germain DA, Spencer DH, Young MA, et al. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers[J].Cancer Cell,2014,25(4):442-454. [10] Holz-Schietinger C, Matje DM, Reich NO. Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation[J].J Biol Chem, 2012,287(37):30941-30951. [11] Kim SJ, Zhao H, Hardikar S, Singh AK, Goodell MA, Chen T. A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells[J].Blood,2013,122(25):4086-4089. [12] Sehgal AR, Gimotty PA, Zhao J, et al. DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia[J].Clin Cancer Res, 2015,21(7):1614-1620. [13] Maes K, De Smedt E, Lemaire M, et al. The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma[J].Oncotarget,2014,5(10):3115-3129. [14] Tsujioka T, Yokoi A, Uesugi M, et al. Effects of DNA methyltransferase inhibitors (DNMTIs) on MDS-derived cell lines[J].Exp Hematol,2013,41(2):189-197. (本文编辑:师晓阳) [收稿日期] 2017-02-07
2017, Vol. 34 
